A Lustman1, S Nakar1, A D Cohen2, S Vinker3. 1. 1] Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel [2] Department of Family Medicine, Central District Clalit Health Services, Rishon Le Zion, Israel. 2. 1] Chief Physician Office, Clalit Health Services Headquarters, Tel Aviv, Israel [2] Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. 3. 1] Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel [2] Chief Physician Office, Clalit Health Services Headquarters, Tel Aviv, Israel.
Abstract
BACKGROUND: Statins have known anticarcinogenic effects; evidence for long-term statin use as effective chemoprevention for prostate cancer is inconsistent. METHODS: We conducted a population-based cohort study to examine the association between statin use and risk of prostate cancer using the Database of Clalit Health Services. A total of 66,741 eligible participants were identified at 1 January 2001 and followed through to 31 December 2009. Cox proportional hazard models were used to compute hazard ratios (HRs) of incident prostate cancer associated with statin therapy controling for patients' clinical and sociodemographic characteristics. RESULTS: A total of 1813 cases of prostate cancer were diagnosed. Statin use was associated with a decreased incidence of prostate cancer, the association was stronger with increasing total dose, hydrophobic statins use and longer periods of treatment. When comparing statin use of over 6 months, this association was strongest for simvastatin (HR 0.51, 95% confidence interval (CI) 0.47-0.56), atorvostatin (HR 0.48, 95% CI 0.33-0.68) and rosuvastatin (HR 0.22, 95% CI 0.08-0.75). CONCLUSIONS: Our findings suggest that prolonged statin use is associated with a reduced risk of prostate cancer; however, this was not true for all types of statin.
BACKGROUND: Statins have known anticarcinogenic effects; evidence for long-term statin use as effective chemoprevention for prostate cancer is inconsistent. METHODS: We conducted a population-based cohort study to examine the association between statin use and risk of prostate cancer using the Database of Clalit Health Services. A total of 66,741 eligible participants were identified at 1 January 2001 and followed through to 31 December 2009. Cox proportional hazard models were used to compute hazard ratios (HRs) of incident prostate cancer associated with statin therapy controling for patients' clinical and sociodemographic characteristics. RESULTS: A total of 1813 cases of prostate cancer were diagnosed. Statin use was associated with a decreased incidence of prostate cancer, the association was stronger with increasing total dose, hydrophobic statins use and longer periods of treatment. When comparing statin use of over 6 months, this association was strongest for simvastatin (HR 0.51, 95% confidence interval (CI) 0.47-0.56), atorvostatin (HR 0.48, 95% CI 0.33-0.68) and rosuvastatin (HR 0.22, 95% CI 0.08-0.75). CONCLUSIONS: Our findings suggest that prolonged statin use is associated with a reduced risk of prostate cancer; however, this was not true for all types of statin.
Authors: Zhenshi Wang; Lanyue Zhang; Zheng Wan; Yan He; Huarong Huang; Hongping Xiang; Xiaofeng Wu; Kun Zhang; Yang Liu; Susan Goodin; Zhiyun Du; Xi Zheng Journal: Pathol Oncol Res Date: 2018-05-24 Impact factor: 3.201
Authors: Esha T Shah; Akanksha Upadhyaya; Lisa K Philp; Tiffany Tang; Dubravka Skalamera; Jennifer Gunter; Colleen C Nelson; Elizabeth D Williams; Brett G Hollier Journal: Clin Exp Metastasis Date: 2016-03-01 Impact factor: 5.150
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: Jacqueline E Reilly; Jeffrey D Neighbors; Huaxiang Tong; Michael D Henry; Raymond J Hohl Journal: Clin Exp Metastasis Date: 2015-06-13 Impact factor: 5.150
Authors: Elizabeth A Platz; Catherine M Tangen; Phyllis J Goodman; Cathee Till; Howard L Parnes; William D Figg; Demetrius Albanes; Marian L Neuhouser; Eric A Klein; M Scott Lucia; Ian M Thompson; Alan R Kristal Journal: J Urol Date: 2014-02-08 Impact factor: 7.450
Authors: Ahmad Ghanizadeh; Motahhar OmraniSigaroodi; Ali Javadpour; Mohammad Hossein Dabbaghmanesh; Sara Shafiee Journal: Depress Res Treat Date: 2014-07-15